Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women

Annals of Internal Medicine

Volumn 127, Issue 7, 1997, Pages 501-508

  Sidney, Stephen ^a,b   Petitti, Diana B ^a,c   Quesenberry Jr , Charles P ^a,b  

^a KAISER PERMANENTE   (United States)

^b DIVISION OF RESEARCH   (United States)

^c Kaiser Permanente Southern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 0030883064     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-7-199710010-00001     Document Type: Article

References (27)

1. Bush TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Korenman SG, ed. The Menopause: Biological and Clinical Consequences of Ovarian Failure. Evolution and Management. Norwell, MA: Serono Symposia; 1990:211-23.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
3. Grady D, Rubin SM, Petitti DB, Fox CS, Black O, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37.
4. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy. Washington, DC: Office of Technology Assessment, Congress of the United States: 1995. OTA-BP-H-144.
5. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54:74-9.
6. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gyraecol. 1992;99:821-8.
7. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994; 154:1333-9.
8. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol. 1993; 137:54-63.
9. Mann RD, Lis Y, Chukwujindu J, Chanter DO. A study of the association between hormone replacement therapy, smoking and occurrence of myocardial infarction in women. J Clin Epidemiol. 1994;47:307-12.
10. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
11. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 1984; 108:150-8.
12. Gillum RF. Cardiovascular disease in the United States: an epidemiologic overview. In: Saunders E, Brest AN, eds. Cardiovascular Diseases in Blacks. Philadelphia: FA Davis; 1991:3-16.
13. Talbott E, Kuller LH, Detre K, Perper J. Biologic and psychosocial risk factors of sudden death from coronary disease in white women. Am J Cardiol. 1977;39:858-64.
14. Byrd BF Jr, Burch JC, Vaughn WK. The impact of long term estrogen support after hysterectomy. A report of 1016 cases. Ann Surg. 1977;185: 574-80.
15. MacMahon B. Cardiovascular disease and noncontraceptive oestrogen therapy. In: Oliver MF, ed. Coronary Heart Disease in Young Women. New York: Churchill Livingstone; 1978:197-207.
16. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischemic heart disease. Lancet. 1981; 1:858-60.
17. Adam S, Williams V, Vessey MP. Cardiovascular disease and hormone replacement treatment: a pilot case-control study. Br Med J (Clin Res Ed). 1981;282:1277-8.
18. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-9.
19. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol. 1987;70:289-93.
20. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogenous community. Am J Epidemiol. 1988; 128:606-14.
21. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990;97:1080-6
22. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-8.
23. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996;87:6-12.
24. Rosenberg L, Armstrong B, Jick H. Myocardial infarction and estrogen therapy in post-menopausal women. N Engl J Med. 1976;294:1256-9.
25. Pfeffer RI, Whipple GH, Kurosaki TT, Chapman JM. Coronary risk and estrogen use in postmenopausal women. Am J Epidemiol. 1978;107:479-87.
26. Bain C, Willett W, Hennekens CH, Rosner B, Belanger C, Speizer FE. Use of postmenopausal hormones and risk of myocardial infarction. Circulation 1981;64:42-6.
27. Hernandez Avila M, Walker AM, Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology. 1990;1:128-33.